1C). 23 The compound showed anti-HIV-1 activity with an IC50 value of 26.9 nM in the defective HIVbased pseudotyped assay, which is also known as the "One-Stone-Two-Birds" protocol ( Figure 1D and Figure S1 , Supporting Information). 20 
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Plant Material (140 g Titration of patentiflorin A (1): Patentiflorin A (1) was shown to inhibit HIV replication with an IC50 value of 26.9 nM in the "One-Stone-Two-Birds" assay. The bioassay experiments (repeated three times each) were performed in triplicate. The pseudoviral evaluation system is described in Figure S1 , Supporting Information.
Patentiflorin A (1), [] MeOH) , was determined to be an arylnaphthalene lignan glycoside containing a methylenedioxy and two methoxy groups by comparison of their 1 H and 13 C NMR data to those of known arylnaphthalene lignans (Table S1, Supporting Information). 24, 25 The lactone carbonyl carbon was assigned at C-9 rather than at C-9 due to the presence of the HMBC cross-peaks of H2-9 to C-7. Analysis of 1D ( 1 H, 13 C and DEPT) and 2D ( 1 H-1 H COSY, HMQC and HMBC) NMR data positioned the two methoxy groups at C-4 and C-5, and the methylenedioxy group at C-3/C-4 to form a piperonyl (1, 3-benzodioxole) group.
Compound 1 was identified as the known compound patentiflorin A by analysis of its spectroscopic data (Table S1 , and Figures S2-S7, Supporting Information), and a comparison with  literature data. 23 We further confirmed the identity by a de novo total synthesis (Schemes 1 and 2) of the compound. The synthesized patentiflorin A (1) gave the same 1 H and 13 C NMR spectroscopic and specific rotation data as those of the natural isolate ( Figure S26 16 Figure 2 . The chemical structures of the synthesized congeners 7-D-xylosyloxydiphyllin (15) and 7-D-glucopyranosyloxydiphyllin (16) .

In addition to patentiflorin A (1), two structural congeners (15 and 16) ( Figure 2 ) were also synthesized and evaluated for potential HIV replication inhibition activities. The synthesis routes for these compounds are summarized in Schemes 1 and 2.
The aglycone diphyllin (10) was determined to be the key intermediate for the synthesis of patentiflorin A (1). The successful synthesis of this intermediate enabled us not only to obtain patentiflorin A but also to afford a synthesis route to other related arylnaphthalene lignan derivatives.
Scheme 1 illustrates our successful synthesis to diphyllin (10) through the key feature of an intermolecular Michael addition reaction of intermediate 6 with furan-2(5H)-one (7) to produce 8. (10) at C-7 with D-quinovose (11) led to patentiflorin A (1) (Scheme 2) Supporting Information) . The MS and NMR data of the synthesized compound being the same as those of the natural isolate confirmed that the two compounds are identical ( Figure S26 , Supporting Information).
Glycosylation of diphyllin
The same strategy for the synthesis of patentiflorin A (1) was employed to synthesize two congeners (15 and 16) . By replacing D-quinovose (11) with D-xylose and D-glucose in Scheme 2, the congeners, 7-D-xylosyloxydiphyllin (15) and 7-D-glucopyranosyloxydiphyllin (16) , were obtained ( Figure 2 and Figures S28-31, Supporting Information), respectively. 7-D-xylosyloxydiphyllin (15, diphyllinin) and 7-D-glucopyranosyloxydiphyllin (16, cleistanthin B) are two natural products that were originally isolated from the aerial parts of Haplophyllum hispanicum 26 
and the bark of
Cleistanthus collinus, 27 respectively.
The biological activities of the natural and synthesized patentiflorin A (1), diphyllin (10) and compounds 15 and 16 were evaluated and compared ( Figure 3 ). As expected, the synthesized patentiflorin A (1) showed similar anti-HIV activity as that of the natural one ( Figure 3A ). However,  compounds 15 and 16 showed much lower anti-HIV activity ( Figure 3D ) than patentiflorin A (1), although these compounds differ from one another only by the sugar units. Although the aglycone diphyllin (10) displayed some level of activity ( Figure 3A) , it is clear that the presence of a sugar unit is required for effective inhibitory action against HIV-1.  activity of the compounds 1, 10 and 15-16 were obtained using the "One-Stone-Two-Birds" evaluation system, with the data obtained from three experiments, each performed in triplicate.
The cytotoxicity of the natural patentiflorin A (1) was initially evaluated in A549 (human alveolar adenocarcinoma) and Hela (human epithelial cervical adenocarcinoma) cell lines. As shown in Figure   3B , at a concentration of 19 M, the natural patentiflorin A exhibited no apparent cytotoxicity to these cells. When the natural and synthesized patentiflorin A (1) were evaluated in PBMC (human peripheral blood mononuclear cell), both displayed the same level of cytotoxicity (CC50: 75 M). 29, 30 To determine the anti-HIV-1 activity spectrum of the natural and synthesized patentiflorin A (1), both were tested against four HIV-1 clinical isolates: BAL and SF162 (both M-tropic), LAV0.04 (Ttropic), and 89.6 (dual tropic) using a standardized human peripheral blood mononuclear cell culture (PBMC) assay. 28 

The results clearly showed that compound 1 is a broad spectrum inhibitor. Like AZT, it inhibited the particle production of all four HIV-1 isolates effectively in a dose-dependent manner ( Figure 3C ).
Compound 1 gave an IC50 value of 24-37 nM, compared to 77-95 nM for AZT, depending on the isolates (Table 1) . As expected, the synthesized patentiflorin A (1) had a similar anti-HIV-1 activity profile compared to that of the natural compound (Table 1) . This finding is important because it validates that both the isolated and synthesized patentiflorin A (1) are active anti-HIV compounds with higher degrees of potency than AZT. Most significantly, the ability to chemically synthesize a potential drug lead such as patentiflorin A (1), would eliminate the need of a dependence for resupply on the phytochemical isolation of the compound from the source plant matrix for drug development efforts, or for commercial production, should it become an approved drug.
The emergence of the drug-resistant HIV isolates is one of the major problems in the long-term treatment of the HIV/AIDS patients. Thus, one critical parameter in the search for novel anti-HIV therapeutics is that a new candidate should have a good therapeutic efficacy against the drug-resistant HIV isolates. Thus, patentiflorin A (1) was investigated to determine whether it was effective against an NRTI (nucleoside reverse transcriptase inhibitor)-resistant isolate (HIV-11617-1) and an NNRTI (non-nucleoside reverse transcriptase inhibitor)-resistant isolate (HIV-1N119) using the PBMC assay as described above. 28 As shown in Table 1 , patentiflorin A (1) effectively inhibited all three of the HIV-1 isolates tested, LAV, HIV-11617-1 and HIV-1N119. In contrast, AZT, as an NRTI, was effective against LAV, HIV-1N119, but not HIV-11617-1, while nevirapine, which is an NNRTI, was effective against LAV, HIV-11617-1, but not against HIV-1N119. 29, 30 These results clearly demonstrate that patentiflorin A (1) is a potent inhibitor against both NRTI-and NNRTI-resistant HIV-1 isolates.
Because of the nature of the initial anti-HIV evaluation protocol employed, it was apparent that patentiflorin A (1) would most likely target a post-entry step in the HIV-1 replication cycle such as  reverse transcription, integration, transcription, or protein expression. To further delineate the mechanism of action of 1, the inhibition profiles of the natural isolate and AZT (control) against HIV gene expression were investigated and compared ( Figure 4 ). HIV gene expression of the R/U5 and U5/gag transcripts was measured using TaqMan-based real time PCR. 31, 32 In this assay, A549 target cells were challenged with a VSV-G/HIV pseudovirus in the presence or absence of the test compound. Hence, patentiflorin A (1), and AZT were added simultaneously with the virus. AZT is a powerful NRTI of HIV that blocks the conversion of viral RNA into DNA. In this assay, AZT blocked R/U5 and U5/gag transcription in a dose-dependent manner with more potent inhibition against the late transcript. In contrast, the test compound (1) was shown to inhibit both the early and late transcripts at levels greater than AZT. The inhibition by 1 is most notable at 0.005 g/mL, with gene expression being decreased by more than 75% as compared to 40% for AZT. These data suggest that patentiflorin A (1) is a potential inhibitor of HIV reverse transcription (RT). Further research is needed to determine the anti-HIV-1 mechanism of action and target of compound 1. Patentiflorin A (1) was isolated and identified as a potent anti-HIV lead compound from the medicinal plant Justicia gendarussa. It displayed broad spectrum activity against both M-tropic and Ttropic HIV-1 isolates with IC50s lower than that of zidovudine (AZT), the first anti-HIV drug developed and still used in the treatment of HIV/AIDS. The de novo total synthesis of the arylnaphthalene lignin (ANL) glycoside was subsequently carried out. We demonstrated that the newly discovered inhibitor targets reverse transcription in the HIV-1 life cycle, and it is highly potent against NRTI-and NNRTI-resistant HIV-1 variants. Therefore, the new inhibitor and its derivatives have potential to be developed as novel anti-HIV therapeutic agents.
A variety of biological activities including antibacterial, antitumor, and anti-HIV activities have been reported for ANL compounds. [33] [34] [35] [36] [37] However, no reported ANL compounds showed the same level of anti-HIV potency as that of patentiflorin A (1). Our data showed that the glycoside patentiflorin A (1) was at least 50-fold more potent than its parent aglycone, diphyllin (10), in inhibiting HIV-1 replication (Figure 3 ).
Patentiflorin A (1) was first isolated from the plant J. patentiflora, and was shown to be cytotoxic in several cancer cell lines with CC50 values in the range of 3-40 nM. 23 However, in our study, the compound showed cytotoxicity at much lower concentrations in several human cell lines. To further characterize 1, the compound was synthesized in order to verify not only its chemical structure but also  its biological activities, as well as being a means of re-supply for future uses. The synthesized patentiflorin A showed similar anti-HIV activity profiles as those of the natural patentiflorin A in all the HIV strains tested, and it demonstrated low toxicity to human PMBC with a CC50 value at 75.5 M (Table 1) .
To further determine the anti-HIV potential and structure relationships among ANL glycosides, two congeners [7-D-xylosyloxydiphyllin (15) and 7-D-glucopyranosyloxydiphyllin (16)] of patentiflorin A (1) were synthesized. Compounds 1, 15 and 16 all contain a sugar unit at C-7. The sugar units differ from one another only by the C-5 substituent, with a methyl group for 1, a hydroxymethyl group for 16 and no substituent at C-5 for 15. It is most interesting to note that with only a slight chemical structural difference at C-5, the three ANL glycosides exhibited such differences in their anti-HIV activity, with 1 being ca. 20-30 times more potent than 15 and 16 ( Figure   3D ). Compound 1 contains a quinovopyranosyloxy sugar unit while 15 and 16 are glycosylated with xylose and glucose, respectively, suggesting that the presence of a quinovopyranosyloxy sugar moiety may be essential to maintain the anti-HIV potency among these three ANL compounds. To fully elucidate the anti-HIV SAR of ANL glycosides, it will be essential to synthesize and evaluate a full complement of other glycosides.
Several aspects of patentiflorin A (1) render it an attractive candidate as a lead compound for anti-HIV-1 drug development. It is a highly potent molecule and has a broad activity spectrum against both M-and T-tropic HIV-1 isolates. The compound was also shown to be more effective than AZT in inhibiting four different HIV-1 isolates, either M-or T-tropic, in human PBMCs with IC50s in the range of 14-32 nM (Table 1) . Further, it demonstrated an excellent selectivity index of 2500. This is the first report that this natural product displayed not only comparable, but higher anti-HIV activity than that of the clinically used drug AZT. were added on the following day at appropriate concentrations and incubated with cells at 37 o C in 5% CO2 for 24 h. After 24 h, all media were removed and replaced with 100 L fresh complete DMEM.
After 48 h post initial addition of DMSO or compound, 20 L of CellTiter 96 Aqueous One Solution was added per well. After gentle mixing, plates were incubated at 37 o C in 5% CO2 for 4 h. Twenty- five L of a 10% SDS solution was added per well and plates were stored at room temperature for approximately 12 h. Absorbance was measured at 450 nm using a plate reader. used to determine the compound susceptibility of these HIV-1 strains. 28 AZT, an anti-HIV drug in clinical use, was used as a positive control. All data were generated from three independent experiments, each performed in triplicate. Prior to HIV-1 infection, human PBMCs were used in each experiment. Briefly, donor PBMCs were suspended in R-3 medium [RPMI 1640 medium supplemented with 15-20% FBS (fetal bovine serum), 5% IL-2 (human interleukin-2), 250 U of penicillin per mL, 250 g of streptomycin per mL and 2 mM L-glutamine] was stimulated with PHA (phytohaemagglutinin, 2-3 µg/mL) for seven days. The preparations (compound or fraction) were  added to the cultured cells, and the different HIV-1 strains were used to challenge the cultured cells in 96-well plates [1  10 5 cells per well with 1000 TCID50 (virus 50% tissue culture infectious doses) of
HIV Gene Expression
HIV strain]. After seven days of incubation, the supernatants were collected and the HIV p24 levels of the infected cells were determined using a p24 antigen ELISA. To measure IC50 values, each drug was tested using seven concentrations (5, 1, 0.2, 0 .04, 0.008, 0.016 and 0 µg/mL). The IC50s were calculated by comparing p24 antigen values for the compounds (fraction)-containing wells with those for no drug control wells. For the p24 assay, the maximum cutoff should be around 120-150 pg/mL. (15 and 16) . A schematic illustration for the synthesis of patentiflorin A (1) is summarized in Schemes 1 and 2. The same synthesis approach was used to synthesize two patentiflorin A congener diphyllin glycosides: 7-D-xylosyloxydiphyllin (15) and 7-D-glucopyranosyloxydiphyllin (16) . 3, 4-Dimethoxybenzaldehyde (veratral, 2a) (10.5 g, 63. 3 mmol) was dissolved in dry, degassed MeOH (250 mL) and stirred under argon. To this solution was added Br2 (3.56 mL, 69.1 mmol), and the reaction mixture was stirred for 6 h at rt. After the completion of the reaction, as indicated by TLC, solvent was removed through evaporation and the resulting mixture was partitioned between CH2Cl2 (250 mL) and a saturated solution of Na2S2O3 (250 mL). The aqueous layer was extracted with CH2Cl2 (2  150 mL), and the combined organic layers were washed with water (250 mL), brine (250 mL), and dried over anhydrous Na2SO4. After the solvent was removed, the residue was purified by silica gel chromatography, eluting with 20% EtOAc  in n-hexane, to afford 2-bromo-4, 5-dimethoxybenzaldehyde (3) as a white foam (13.4 g, 86%) : 2- 3] dithiane (4) . To a flask containing dry benzene (300 mL), the bromoaldehyde (3) CH2, C-S1 and C-S3), 25.1 (CH2, C-S2).
Chemical Synthesis of Patentiflorin A (1) and Its Glycoside Congeners
Benzo [1, 3] dioxol-5-yl- (2-[1, 3] dithian-2-yl-4, 5-dimethoxyphenyl)methanol (5) . To a solution of the dithiane (4) (CH3, OCH3), 47.9 (CH, C-7), 32.6 (CH2, C-S1 or C-S3), 32.5 (CH2, C-S3 or C-S1), 25.1 (CH2, C-S2).
Benzo [1, 3] dioxol-5-yl- (2-[1,3] dithian -2-yl-4,5-dimethoxyphenyl) methanone (6) . 
